Guidance and quality standards awaiting development

Showing 301 to 310 of 312

Guidance and quality standards awaiting development
Title	Type
Vosoritide for treating achondroplasia in children TSID 12001	Technology appraisal guidance
Vosoritide for treating achondroplasia in children and young people under 18 years [ID3807]	Technology appraisal guidance
WP1048 for treating grass pollen allergy in people aged 18 to 60 TS ID 10467	Technology appraisal guidance
Xeomin (botulinum neurotoxin type A) for treating lower limb spasticity TS ID 11902	Technology appraisal guidance
Xevinapant with platinum-based chemotherapy and radiotherapy for untreated locally advanced squamous cell head and neck cancer [ID6199]	Technology appraisal guidance
Zamtocabtagene autoleucel for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more therapies TS ID 10765	Technology appraisal guidance
Zamtocabtagene autoleucel for treating relapsed or refractory diffuse large B-cell lymphoma when high-dose chemotherapy and autologous stem cell transplant are unsuitable TS ID 10477	Technology appraisal guidance
Zanidatamab for treating HER2-positive advanced biliary tract cancer after 1 or more systemic treatments TS ID 11952	Technology appraisal guidance
Zanubrutinib with obinutuzumab for treating relapsed or refractory B-cell follicular lymphoma after 2 or more treatments [ID6416]	Technology appraisal guidance
Zavegepant for treating acute migraine TSID 11998	Technology appraisal guidance